JPRN-UMIN000005270已完成未知
Evaluation of optimal 5ASA dose in order to determine for keeping remission of patients with ulcerative colitis by colonoscopy using FICE (flexible spectral imaging color enhancement) system. - Determination of optimal 5ASA dose for keeping remission of UC patients by FICE colonoscopy
Saitama Medical Center, Saitama Medical University0 个研究点目标入组 180 人开始时间: 2011年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who cannot accept colonoscopy Patients who have no agreement of this study Patients who is pregnant or possibly be pregnant Patients who had operation of total or partial colectomy Patients who got to start to take treamtents such as; -sterids (intravenous, peroral, enema and suppo) within 4 weeks -metrinidazole within 4 weeks -infliximab within 4 weeks -elemental diet or IVH within 4 weeks -cyclosporine or tacrolimus within 4 weeks -azathiopurine or 6MP within 4 weeks -mesalazine enema or suppo within 4 weeks -increase or decrease the mesalazine dose within 4 weeks
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the optimal dose of prophylactic anticoagulation with low- molecular- weight heparin administered subcutaneously to critically ill patients – part 2 - LMWH prophylaxis for ICU patientsMedDRA version: 12.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisvenous thromboembolismEUCTR2010-022034-88-DKOdense University Hospital
进行中（未招募）
1 期
Evaluation of the optimal dose of prophylactic anticoagulation with low-molecular-weight heparine administered subcutaneously to critically ill patients - low-molecular-weight heparin in critically ill patientsEUCTR2005-002381-10-DKDept anaesthesiology and intensive care80
已完成
不适用
Observational research to decide optimal dose of Afatinib in patients with primary lung adenocarcinoma harbouring the sensitive mutation of epidermal growth factor receptor (EGFR) by pharmacokinetic analysesPatients have primary lung adenocarcinoma harbouring the sensitive mutation of epidermal growth factor receptor (EGFR)JPRN-UMIN000033549Department of Respiratory Medicine in the Center Hospital of the National Center for Global health and Medicine1
尚未招募
不适用
A clinical study to determine the optimal dose of WIN-1001X by evaluating its efficacy and safety in patients with early Parkinson’s diseaseDiseases of the nervous systemKCT0004536Medihelpline188
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90